Abbott Buys CSI To Add Peripheral And Coronary Atherectomy Technologies

CSI markets minimally invasive devices to remove vascular plaques and has a full pipeline of complementary vascular intervention technologies. Abbott expects CSI’s products to complement its existing coronary intervention business and expand its presence in the peripheral market.

ddd
• Source: Shutterstock

Wall Street analysts support Abbott’s planned $890m acquisition of Cardiovascular Systems (CSI) as a relatively inexpensive way for Abbott to expand its presence in the peripheral intervention market.

Under the terms of the deal announced late on 8 February, Abbott has agreed to acquire CSI for $20 per...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By 

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By 

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Philips Deals Itself A Strong Hand In POCUS Stakes

 
• By 

Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.